Home/Pipeline/Bispecific Antibody

Bispecific Antibody

Solid Tumors

Phase 1/2Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Akeso

About Akeso

Akeso Inc. is a clinical-stage biopharmaceutical company headquartered in China, specializing in the research, development, and commercialization of innovative cancer immunotherapies. The company has built a robust pipeline of immune checkpoint inhibitors and bispecific antibodies, with several candidates in late-stage clinical trials. As a publicly traded company on the Hong Kong Stock Exchange, Akeso represents one of China's most promising biotech companies in the oncology space.

View full company profile

Therapeutic Areas

Oncology Immunotherapy

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active
ONO-4538 combinations	Ono Pharmaceutical	Phase 2	Active